For several start-ups that are resident at JLABS @ Toronto, not even COVID-19 has paused their plans to recruit talent and scale up; they counted on Mitacs’s programs to help set their businesses up for potential success.
As businesses, municipalities, and not-for-profit organizations face unprecedented challenges during the COVID-19 pandemic, Mitacs’s new offering of Business Strategy Internships serves to support local operations.
Multidisciplinary team led by University of Winnipeg researchers develops robotic system that automatically generates and labels large datasets of prairie crop plants and weeds to unlock innovation in food production
As cancer remains one of the leading causes of mortality worldwide, CanPRIME may prove to be a gift to many. The unique training program bolsters Canada’s capacity to manufacture COVID-19 vaccines, as well as viral immunotherapies for cancer.
A collaborative project supported by Mitacs utilizes research and industry expertise to produce faster and higher volume of manufacturing solutions for PPE and other products that address transmission of COVID-19.
Entrepreneur and former Mitacs intern Andrée-Ann Adam’s invention prevents gum disease, improving the health of pets’ teeth. Now her small business is on a trajectory for success thanks to increasing demand.
A Globalink Research Internship leads to graduate studies in Canada for the founder of NuPort Robotics, the country’s first autonomous trucking company that uses eco-friendly, self-driving electric trucks for short-haul drives.
University of Regina researchers team up with residents of Île-à-la-Crosse, Saskatchewan, on a platform to support enduring solutions to the COVID-19 crisis. The initiative has the potential to expand beyond the region and address other challenges.
In many remote locations, access to medical supplies, which can make the difference between a speedy recovery and death, can be limited because of their sensitivity to temperature variations during transport.
One company that’s addressing the need for a vaccine is Medicago, a biopharmaceutical company that’s using a new manufacturing technology based on Plants and Virus-like Particles (VLP). Medicago is creating a vaccine that has the potential to promote antibody production, and unlike cell culture systems, plant systems do not require complicated growth or storage conditions.